NeutriSci Announces Voluntary Delisting from OTCQB

VANCOUVER, BCJan. 26, 2022 /CNW/ – NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSXV: NU) (OTCQB: NRXCF) (FSE: 1N9), an innovative technology company developing products, licensing IP and technology for B2B partnerships and the nutraceutical industry, announces that, it in order to direct capital to other activities, will voluntarily delist its common shares from trading on the OTCQB.  The delisting will be effective prior to the opening of the markets on February 1, 2022.

NeutriSci Logo (CNW Group/NeutriSci International Inc.)

The Company expects its common shares may thereafter be eligible for quotation on the Pink tier of OTC Markets Group if market makers commit to making a market in the Company’s shares. The Company can provide no assurance that trading in its common shares will continue on the OTC Markets Group or otherwise. For quotes or additional information on the OTC Pink market, please visit

The Company’s shares will continue to trade on the TSXV, and the FSE.

About NeutriSci International Inc.

NeutriSci specializes in the innovation, production, and formulation of nutraceutical products. Established in 2009, NeutriSci’s is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for its products offering co-branding as well as private label opportunities and contract manufacturing services. For more information, please visit:

On Behalf of the Board of Directors of

Glen Rehman
Tel: (403) 264-6320

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking.  Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements.  Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions.  There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties.  We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure, or prevent any disease.


SOURCE NeutriSci International Inc.


Cision View original content to download multimedia: